No significant strengths identified
| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| VSEEWVSee Health, Inc. | 1.52M | 0.09 | -0.02 | 78.42% | -85.76% | |||
| VSEEVSee Health, Inc. | 14.7M | 0.44 | -0.08 | 80.74% | -85.76% | |||
| MGRXMangoceuticals, Inc. | 10.82M | 0.66 | -0.15 | -15.81% | -42.45% | -126.03% | 0.02 | |
| BEATHeartBeam, Inc. | 75.78M | 2.20 | -3.01 | -50.79% | ||||
| OMDAOmada Health | 906.26M | 15.65 | -18.41 | 38.29% | -16.82% | -16.98% | 0.47 | |
| HNGEHinge Health, Inc. | 1.66B | 43.76 | -291.73 | 33.37% | -3.06% | -2.83% | 2.73% | 0.03 |
| Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|
| Sales/Revenue | 6.8M | 7.34M | 6.38M | 5.77M | 10.42M |
| Revenue Growth % | - | 0.08% | -0.13% | -0.1% | 0.81% |
| Cost of Goods Sold | 1.34M | 1.41M | 1.54M | 1.93M | 3.24M |
| COGS % of Revenue | 0.2% | 0.19% | 0.24% | 0.34% | 0.31% |
| Gross Profit | 5.46M | 5.92M | 4.84M | 3.83M | 7.18M |
| Gross Margin % | 0.8% | 0.81% | 0.76% | 0.66% | 0.69% |
| Gross Profit Growth % | - | 0.08% | -0.18% | -0.21% | 0.87% |
| Operating Expenses | 5.06M | 5.67M | 6.52M | 5.71M | 69.33M |
| OpEx % of Revenue | 0.74% | 0.77% | 1.02% | 0.99% | 6.65% |
| Selling, General & Admin | 5.06M | 282.67K | 6.3M | 5.38M | 11.86M |
| SG&A % of Revenue | 0.74% | 0.04% | 0.99% | 0.93% | 1.14% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| R&D % of Revenue | - | - | - | - | - |
| Other Operating Expenses | 0 | 5.39M | 216.03K | 326.64K | 57.47M |
| Operating Income | 404.5K | 252.28K | -1.68M | -1.87M | -62.15M |
| Operating Margin % | 0.06% | 0.03% | -0.26% | -0.32% | -5.96% |
| Operating Income Growth % | - | -0.38% | -7.66% | -0.12% | -32.17% |
| EBITDA | 0 | 0 | -216.03K | -1.87M | -60.83M |
| EBITDA Margin % | - | - | -0.03% | -0.32% | -5.84% |
| EBITDA Growth % | - | - | - | -7.67% | -31.48% |
| D&A (Non-Cash Add-back) | -404.5K | -252.28K | 1.46M | 678 | 1.32M |
| EBIT | 404.5K | 252.28K | -1.46M | -1.79M | -4.68M |
| Net Interest Income | 45.03K | 1.97K | 796.66K | -1.82M | -211.46K |
| Interest Income | 45.03K | 1.97K | 922.64K | 358.77K | 0 |
| Interest Expense | 0 | 0 | 125.98K | 2.18M | 211.46K |
| Other Income/Expense | -45.03K | 134.06K | 59.92K | -13.38K | 2.81M |
| Pretax Income | 359.47K | 386.34K | -1.62M | -1.89M | -59.34M |
| Pretax Margin % | 0.05% | 0.05% | -0.25% | -0.33% | -5.69% |
| Income Tax | 100.59K | 108.11K | -694.36K | 1.84M | -1.64M |
| Effective Tax Rate % | 0.72% | 1.23% | 0.52% | 1.99% | 0.97% |
| Net Income | 258.88K | 475.9K | -836.21K | -3.76M | -57.7M |
| Net Margin % | 0.04% | 0.06% | -0.13% | -0.65% | -5.54% |
| Net Income Growth % | - | 0.84% | -2.76% | -3.5% | -14.33% |
| Net Income (Continuing) | 258.88K | 278.23K | -925.75K | -3.73M | -57.7M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | -362.75K | -325.28K | 0 |
| EPS (Diluted) | 0.03 | 0.05 | -0.08 | -0.38 | -5.65 |
| EPS Growth % | - | 0.84% | -2.75% | -3.55% | -13.87% |
| EPS (Basic) | 0.03 | 0.05 | -0.08 | -0.38 | -5.65 |
| Diluted Shares Outstanding | 9.97M | 9.95M | 10M | 10M | 10.21M |
| Basic Shares Outstanding | 9.97M | 9.95M | 10M | 10M | 10.21M |
| Dividend Payout Ratio | - | - | - | - | - |
| Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|
| Total Current Assets | 1.48M | 1.22M | 759.78K | 802.13K | 3.02M |
| Cash & Short-Term Investments | 775.24K | 760.01K | 230.66K | 118.73K | 326.12K |
| Cash Only | 775.24K | 760.01K | 230.66K | 118.73K | 326.12K |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 659.04K | 286.09K | 389.45K | 628.48K | 2.25M |
| Days Sales Outstanding | 35.35 | 14.23 | 22.29 | 39.78 | 78.74 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - |
| Other Current Assets | 0 | 26.29K | 0 | -25K | 446.83K |
| Total Non-Current Assets | 1.25M | 116.73M | 1.85M | 3.66K | 16.97M |
| Property, Plant & Equipment | 0 | 0 | 0 | 3.66K | 1.06M |
| Fixed Asset Turnover | - | - | - | 1576.67x | 9.83x |
| Goodwill | 0 | 0 | 0 | 0 | 4.92M |
| Intangible Assets | 0 | 0 | 0 | 0 | 10.99M |
| Long-Term Investments | 0 | 116.73M | 0 | 1.37M | 0 |
| Other Non-Current Assets | 1.25M | 0 | 1.85M | -1.37M | 0 |
| Total Assets | 2.73M | 117.94M | 2.61M | 805.79K | 19.99M |
| Asset Turnover | 2.50x | 0.06x | 2.44x | 7.16x | 0.52x |
| Asset Growth % | - | 42.26% | -0.98% | -0.69% | 23.81% |
| Total Current Liabilities | 2.11M | 184.06K | 2.61M | 5.11M | 19.01M |
| Accounts Payable | 311.24K | 202.45K | 687.82K | 187.22K | 4.28M |
| Days Payables Outstanding | 84.75 | 52.28 | 162.74 | 35.35 | 481.98 |
| Short-Term Debt | 133.08K | 0 | 517.13K | 543K | 8.28M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 902.52K | 417.81K |
| Other Current Liabilities | 1.67M | -18.39K | 1.23M | 1.5M | 2.51M |
| Current Ratio | 0.70x | 6.62x | 0.29x | 0.16x | 0.16x |
| Quick Ratio | 0.70x | 6.62x | 0.29x | 0.16x | 0.16x |
| Cash Conversion Cycle | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 4.37M | 0 | 4.37M | 1M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 593.94K |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 269.34K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 67.38K |
| Other Non-Current Liabilities | 0 | 4.37M | 0 | 4.37M | 0 |
| Total Liabilities | 2.11M | 4.55M | 2.61M | 5.11M | 20.01M |
| Total Debt | 133.08K | 0 | 517.13K | 543K | 9.55M |
| Net Debt | -642.16K | -760.01K | 286.47K | 424.27K | 9.22M |
| Debt / Equity | 0.22x | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - |
| Interest Coverage | - | - | -13.34x | -0.86x | -293.91x |
| Total Equity | 614.49K | 113.39M | -2.03K | -4.3M | -18.49K |
| Equity Growth % | - | 183.53% | -1% | -2113.86% | 1% |
| Book Value per Share | 0.06 | 11.40 | -0.00 | -0.43 | -0.00 |
| Total Shareholders' Equity | 614.49K | 113.39M | 360.72K | -3.97M | -18.49K |
| Common Stock | 985 | 116.73M | 1K | 464 | 1.63K |
| Retained Earnings | -5.38M | -3.33M | -5.67M | -10M | -67.7M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | -362.75K | -325.28K | 0 |
| Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|
| Cash from Operations | 789.12K | -600.11K | -1.45M | -632.6K | -5.79M |
| Operating CF Margin % | 0.12% | -0.08% | -0.23% | -0.11% | -0.56% |
| Operating CF Growth % | - | -1.76% | -1.42% | 0.56% | -8.15% |
| Net Income | 258.88K | -280.7K | -3.24M | -3.73M | -57.7M |
| Depreciation & Amortization | 0 | 0 | 0 | 678 | 1.38M |
| Stock-Based Compensation | 0 | 0 | 0 | 0 | 896.54K |
| Deferred Taxes | 0 | 0 | 0 | 1.85M | -1.68M |
| Other Non-Cash Items | 1.16M | -1.97K | -727.47K | -71.87K | 54.52M |
| Working Capital Changes | -629.07K | -317.44K | 2.52M | 1.31M | -3.21M |
| Change in Receivables | -604.06K | 0 | 0 | -246.48K | -839.81K |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 0 | 0 | 1.41M | -1.45M |
| Cash from Investing | 0 | -116.73M | 110.12M | -4.33K | -26.14K |
| Capital Expenditures | 0 | 0 | 0 | -4.33K | -55.27K |
| CapEx % of Revenue | - | 0% | 0% | 0% | 0.01% |
| Acquisitions | - | - | - | - | - |
| Investments | - | - | - | - | - |
| Other Investing | 0 | 0 | 110.47M | 0 | 0 |
| Cash from Financing | -83.67K | 118.09M | -109.32M | 525K | 6.02M |
| Debt Issued (Net) | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - |
| Other Financing | -83.67K | 118.66M | 0 | 135K | 1.27M |
| Net Change in Cash | - | - | - | - | - |
| Free Cash Flow | 789.12K | -600.11K | -1.45M | -636.93K | -5.84M |
| FCF Margin % | 0.12% | -0.08% | -0.23% | -0.11% | -0.56% |
| FCF Growth % | - | -1.76% | -1.42% | 0.56% | -8.18% |
| FCF per Share | 0.08 | -0.06 | -0.15 | -0.06 | -0.57 |
| FCF Conversion (FCF/Net Income) | 3.05x | -1.26x | 1.74x | 0.17x | 0.10x |
| Interest Paid | 0 | 0 | 0 | 0 | 111.33K |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 |
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Return on Equity (ROE) | 42.13% | 0.83% | -1.47% | - | - |
| Return on Invested Capital (ROIC) | - | 0.34% | -2.23% | - | -1749.8% |
| Gross Margin | 80.3% | 80.74% | 75.81% | 66.47% | 68.87% |
| Net Margin | 3.8% | 6.49% | -13.11% | -65.26% | -553.69% |
| Debt / Equity | 0.22x | - | - | - | - |
| Interest Coverage | - | - | -13.34x | -0.86x | -293.91x |
| FCF Conversion | 3.05x | -1.26x | 1.74x | 0.17x | 0.10x |
| Revenue Growth | - | 7.82% | -13.08% | -9.59% | 80.74% |
| 2024 | |
|---|---|
| Subscription and Circulation | 4.12M |
| Subscription and Circulation Growth | - |
| Technology Service | 1.98M |
| Technology Service Growth | - |
| Health Care, Patient Service | 1.21M |
| Health Care, Patient Service Growth | - |
VSee Health, Inc. (VSEE) reported $14.6M in revenue for fiscal year 2024. This represents a 114% increase from $6.8M in 2020.
VSee Health, Inc. (VSEE) grew revenue by 80.7% over the past year. This is strong growth.
VSee Health, Inc. (VSEE) reported a net loss of $12.5M for fiscal year 2024.
VSee Health, Inc. (VSEE) had negative free cash flow of $4.5M in fiscal year 2024, likely due to heavy capital investments.